104 related articles for article (PubMed ID: 10457421)
1. Transient response of myeloma clone to pamidronate therapy.
Corso A; Astori C; Orlandi E; Zappasodi P; Arcaini L; Bernasconi C
Haematologica; 1999 Aug; 84(8):759-60. PubMed ID: 10457421
[No Abstract] [Full Text] [Related]
2. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
3. Perspective study on pamidronate in stage I multiple myeloma.
Caparrotti G; Catalano L; Feo C; Vallone R; Pagnini D; Rotoli B
Hematol J; 2003; 4(6):459-60. PubMed ID: 14671624
[No Abstract] [Full Text] [Related]
4. Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient.
Trimarchi H; Lombi F; Forrester M; Elizondo C; Sawinski D; Pereyra H; Freixas E
Nat Clin Pract Nephrol; 2006 Aug; 2(8):459-63; quiz 464. PubMed ID: 16932480
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma.
Bataille R; Harousseau JL
N Engl J Med; 1997 Jun; 336(23):1657-64. PubMed ID: 9171069
[No Abstract] [Full Text] [Related]
7. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms behind the anti-tumour effects of zoledronic acid use in multiple myeloma.
Ararat E; Sahin I; Ozdemir E; Altundag K
Br J Haematol; 2010 Dec; 151(5):530-1. PubMed ID: 20880117
[No Abstract] [Full Text] [Related]
9. Nephrotic syndrome after treatment with pamidronate.
Markowitz GS; Fine PL; D'agati VD
Am J Kidney Dis; 2002 May; 39(5):1118-22. PubMed ID: 11979358
[No Abstract] [Full Text] [Related]
10. Osteitis fibrosa cystica and secondary hyperparathyroidism in multiple myeloma.
Bains MA; Pardoe LE; Rudin CE
Br J Haematol; 2007 Jan; 136(2):179. PubMed ID: 17062009
[No Abstract] [Full Text] [Related]
11. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
[TBL] [Abstract][Full Text] [Related]
12. Geraldine Ferraro. The fight of her life. Interview by Jo Cavallo.
Ferraro G
InTouch; 2002 Sep; 4(5):24-6, 33. PubMed ID: 12398056
[No Abstract] [Full Text] [Related]
13. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
[TBL] [Abstract][Full Text] [Related]
14. Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients--the American experience.
Berenson J
Br J Clin Pract Suppl; 1996 Sep; 87():5-7; discussion 13-4. PubMed ID: 8995010
[No Abstract] [Full Text] [Related]
15. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Ciepłuch H; Baran W; Hellmann A
Med Sci Monit; 2002 Apr; 8(4):PI31-6. PubMed ID: 11951079
[TBL] [Abstract][Full Text] [Related]
16. [Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma].
Leng Y; Chen SL; Shi HZ
Space Med Med Eng (Beijing); 2002 Oct; 15(5):377-8. PubMed ID: 12449148
[TBL] [Abstract][Full Text] [Related]
17. Anti-myeloma activity of pamidronate in vivo.
Dhodapkar MV; Singh J; Mehta J; Fassas A; Desikan KR; Perlman M; Munshi NC; Barlogie B
Br J Haematol; 1998 Nov; 103(2):530-2. PubMed ID: 9827929
[TBL] [Abstract][Full Text] [Related]
18. Home care versus hospital care in patients with multiple myeloma treated with pamidronate.
Smith AG; Soutar RL; Schey S; Andrews CD; Baister ER; Bilbrough C; Connelly M; Joyce A; Child JA
Int J Palliat Nurs; 2004 Mar; 10(3):144-9. PubMed ID: 15126959
[TBL] [Abstract][Full Text] [Related]
19. Morphoproteomic expression of H-ras (p21ras) correlates with serum monoclonal immunoglobulin reduction in multiple myeloma patients following pamidronate treatment.
Zhang PL; Quiery AT; Blasick TM; Brown RE
Ann Clin Lab Sci; 2007; 37(1):34-8. PubMed ID: 17311867
[TBL] [Abstract][Full Text] [Related]
20. [New attitudes to pain control in multiple myeloma].
Dolev E; Meytes D
Harefuah; 1992 Dec; 123(12):535-6. PubMed ID: 1289203
[No Abstract] [Full Text] [Related]
[Next] [New Search]
